Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30699773 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL27874181 | 0.82 | RAPGEF4 (0.31) | RAPGEF4 | |
| SCHEMBL14498187 | 0.82 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1RAPGEF4ALDH2 | |
| SCHEMBL12653027 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL8363463 | 0.78 | RAPGEF4 (0.34) | RAPGEF4 | |
| SCHEMBL9675381 | 0.76 | POLB (0.37) | ALDH1A1TSHRCYP3A4TDP1MAPK1 | |
| SCHEMBL25245189 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL432164 | 0.75 | GAA (0.50) | GAAMAPTCA1POLBL3MBTL1 | |
| SCHEMBL8840849 | 0.75 | RAPGEF4 (0.39) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL22102332 | 0.75 | RAPGEF4 (0.39) | ALDH1A1RAPGEF4CA1ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| WO-2025049274-A2 | TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| CN-102596937-A | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2012-07-18 | — | — | CN | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2010012396-A1 | 5,6 SUBSTITUTED BENZAMIDE DERIVATIVES AS MODULATORS OF THE EP<SB>2 </SB>RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149552-A1 | 5,6 substituted benzamide derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | ALDH1A1 3869/4885KDM4E 1176/4885LMNA 2621/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | ALDH1A1 1000/4885KDM4E 553/4885LMNA 4245/4885 |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | ALDH1A1 2062/4885KDM4E 2255/4885LMNA 2539/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | ALDH1A1 1275/4885KDM4E 3316/4885LMNA 3135/4885 |
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | SCN1B, OXER1, NR3C2 | ALDH1A1 970/4885KDM4E 1358/4885LMNA 3075/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 908/4885KDM4E 981/4885LMNA 3592/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | ALDH1A1 3869/4885KDM4E 1176/4885LMNA 2621/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | ALDH1A1 1000/4885KDM4E 553/4885LMNA 4245/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | ALDH1A1 3869/4885KDM4E 1176/4885LMNA 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.